David Ricks, Eli Lilly CEO Photographer: Al Drago/Bloomberg via Getty Images

FDA ad­vi­sors back Lil­ly’s Alzheimer’s drug, set­ting stage for ap­proval af­ter de­lay

An FDA ad­vi­so­ry com­mit­tee gave its strong back­ing to Eli Lil­ly’s Alzheimer’s drug do­nanemab, giv­ing fur­ther sup­port for the agency’s ex­pect­ed ap­proval af­ter a sur­prise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.